Examination of CD302 as a potential therapeutic target for acute myeloid leukemia
Open Access
- 10 May 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (5) , e0216368
Abstract
Acute myeloid leukemia (AML) is the most common form of adult acute leukemia with ~20,000 new cases yearly. The disease develops in people of all ages, but is more prominent in the elderly, who due to limited treatment options, have poor overall survival rates. Monoclonal antibodies (mAb) targeting specific cell surface molecules have proven to be safe and effective in different haematological malignancies. However, AML target molecules are currently limited so discovery of new targets would be highly beneficial to patients. We examined the C-type lectin receptor CD302 as a potential therapeutic target for AML due to its selective expression in myeloid immune populations. In a cohort of 33 AML patients with varied morphological and karyotypic classifications, 88% were found to express CD302 on the surface of blasts and 80% on the surface of CD34+ CD38- population enriched with leukemic stem cells. A mAb targeting human CD302 was effective in mediating antibody dependent cell cytotoxicity and was internalised, making it amenable to toxin conjugation. Targeting CD302 with antibody limited in vivo engraftment of the leukemic cell line HL-60 in NOD/SCID mice. While CD302 was expressed in a hepatic cell line, HepG2, this molecule was not detected on the surface of HepG2, nor could HepG2 be killed using a CD302 antibody-drug conjugate. Expression was however found on the surface of haematopoietic stem cells suggesting that targeting CD302 would be most effective prior to haematopoietic transplantation. These studies provide the foundation for examining CD302 as a potential therapeutic target for AML.Keywords
Funding Information
- National Health and Medical Research Council (543727)
- Cancer Institute NSW (11/TPG/3-02)
This publication has 18 references indexed in Scilit:
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trialsThe Lancet Oncology, 2014
- Antibody therapy for acute myeloid leukaemiaBritish Journal of Haematology, 2013
- Selective elimination of leukemia stem cells: Hitting a moving targetCancer Letters, 2013
- Acute myelogenous leukemia stem cells: From Bench to BedsideCancer Letters, 2013
- Identifying leukemia stem cells – Is it feasible and does it matter?Cancer Letters, 2012
- Anti-CD20 Antibody Therapy for B-Cell LymphomasNew England Journal of Medicine, 2012
- Therapeutic Advances in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2011
- Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcomeBlood, 2009
- Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemiaBlood, 2005
- Hodgkin's Lymphoma Cell Lines Express a Fusion Protein Encoded by Intergenically Spliced mRNA for the Multilectin Receptor DEC-205 (CD205) and a Novel C-type Lectin Receptor DCL-1Journal of Biological Chemistry, 2003